MENU
Showcases Stock ranks Forex

Exelixis Inc (EXEL)
21.55  0.03 (0.14%) 08-08 16:00
Open: 21.75 Pre. Close: 21.52
High: 22.0401 Low: 21.2
Volume: 2,235,557 Market Cap: 6,912M
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 22.066 - 22.151 22.151 - 22.236
Low: 20.98 - 21.08 21.08 - 21.181
Close: 21.388 - 21.542 21.542 - 21.696
Stock Technical Analysis
Overall:     
Target: Six months: 26.24
One year: 30.65
Support: Support1: 21.14
Support2: 20.31
Resistance: Resistance1: 22.47
Resistance2: 26.24
Pivot: 21.31
Moving Averages: MA(5): 21.48
MA(20): 21.33
MA(100): 20.89
MA(250): 19.91
MACD: MACD(12,26): 0.17
Signal(12,26,9): 0.20
%K %D: %K(14,3): 64.86
%D(3): 62.86
RSI: RSI(14): 55.34
52-Week: High: 23.4
Low: 15.5
Change(%): 16.5
Average Vol(K): 3-Month: 2843
10-Days: 1693
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ EXEL ] has closed below upper band by 32.7%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Mon, 08 Aug 2022
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More - Nasdaq

Sun, 07 Aug 2022
Russell Investments Group Ltd. Sells 108099 Shares of Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Sat, 06 Aug 2022
Head-To-Head Analysis: Exelixis (NASDAQ:EXEL) & ImmunityBio (NASDAQ:IBRX) - Defense World

Thu, 04 Aug 2022
EXEL: 2 Stocks to Buy at a Discount Right Now - StockNews.com

Tue, 02 Aug 2022
Exelixis (EXEL) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Mon, 01 Aug 2022
Arizona State Retirement System Boosts Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 320.74
% Held by Insiders 298780000.00
% Held by Institutions 1.99
Shares Short (K) 12000
Shares Short Prior Month (K)
Stock Financials
EPS 0.920
Book Value (p.s.) 114.300
Profit Margin 19.60
Operating Margin 24.63
Return on Assets (ttm) 9.7
Return on Equity (ttm) 14.2
Qtrly Rev. Growth 31.7
Gross Profit (p.s.) 2300000000.000
Sales Per Share 2533333248.000
EBITDA (p.s.) 649016640.000
Qtrly Earnings Growth 4.00
Operating Cash Flow (M)
Levered Free Cash Flow (M) 508.98
Stock Valuation
PE Ratio 23.42
PEG Ratio 0.52
Price to Book value 0.19
Price to Sales
Price to Cash Flow 1.81
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 9970000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android